RT Journal Article
T1 Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG).
A1 Dittner-Moormann, Sabine
A1 Reschke, Madlen
A1 Abbink, Floor C H
A1 Aerts, Isabelle
A1 Atalay, Hatice Tuba
A1 Fedorovna Bobrova, Nadezhda
A1 Biewald, Eva
A1 Brecht, Ines B
A1 Caspi, Shani
A1 Cassoux, Nathalie
A1 Castela, Guilherme
A1 Diarra, Yelena
A1 Duncan, Catriona
A1 Ebinger, Martin
A1 Garcia Aldana, David
A1 Hadjistilianou, Doris
A1 Kepák, Tomáš
A1 Klett, Artur
A1 Kiratli, Hayyam
A1 Maka, Erika
A1 Opocher, Enrico
A1 Pawinska-Wasikowska, Katarzyna
A1 Rascon, Jelena
A1 Russo, Ida
A1 Rutynowska-Pronicka, Olga
A1 Sábado Álvarez, Constantino
A1 Pacheco, Sonsoles San Roman
A1 Svojgr, Karel
A1 Timmermann, Beate
A1 Vishnevskia-Dai, Vicktoria
A1 Eggert, Angelika
A1 Ritter-Sovinz, Petra
A1 Bechrakis, Nikolaos E
A1 Jenkinson, Helen
A1 Moll, Annette
A1 Munier, Francis L
A1 Popovic, Maja Beck
A1 Chantada, Guillermo
A1 Doz, François
A1 Ketteler, Petra
K1 RB1 gene
K1 biomarker
K1 chemotherapy
K1 childhood cancer
K1 metastasis
K1 radiotherapy
AB Advanced intraocular retinoblastoma can be cured by enucleation, but spread of retinoblastoma cells beyond the natural limits of the eye is related to a high mortality. Adjuvant therapy after enucleation has been shown to prevent metastasis in children with risk factors for extraocular retinoblastoma. However, histological criteria and adjuvant treatment regimens vary and there is no unifying consensus on the optimal choice of treatment. Data on guidelines for adjuvant treatment in European retinoblastoma referral centres were collected in an online survey among all members of the European Retinoblastoma Group (EURbG) network. Extended information was gathered via personal email communication. Data were collected from 26 centres in 17 countries. Guidelines for adjuvant treatment were in place at 92.3% of retinoblastoma centres. There was a consensus on indication for and intensity of adjuvant treatment among more than 80% of all centres. The majority of centres use no adjuvant treatment for isolated focal choroidal invasion or prelaminar optic nerve invasion. Patients with massive choroidal invasion or postlaminar optic nerve invasion receive adjuvant chemotherapy, while microscopic invasion of the resection margin of the optic nerve or extension through the sclera are treated with combined chemo- and radiotherapy. Indications and adjuvant treatment regimens in European retinoblastoma referral centres are similar but not uniform. Further biomarkers in addition to histopathological risk factors could improve treatment stratification. The high consensus in European centres is an excellent foundation for a common European study with prospective validation of new biomarkers.
YR 2021
FD 2021-03-15
LK http://hdl.handle.net/10668/17353
UL http://hdl.handle.net/10668/17353
LA en
DS RISalud
RD Apr 12, 2025